Botulinum toxin in the treatment of patients with temporomandibular dysfunction and headache: A scope review
DOI:
https://doi.org/10.33448/rsd-v13i3.45119Keywords:
Temporomandibular joint dysfunction syndrome; Headache disorders; Migraine; Botulinum toxin type A.Abstract
Temporomandibular dysfunction (TMD) and headaches are challenging health issues and represent the second cause of chronic facial pain in the world population. They present convergence in treatment, with botulinum toxin being a second-line resource for refractory cases. With the aim of mapping information on the topic, this scoping review was carried out using the elements of the PCC acronym to formulate the question: “What has been produced in the literature about the use of botulinum toxin A in patients with TMD and headache refractory to initial therapy?”. The population was defined by patients with TMD and headaches; in the concept, botulinum toxin A was used in the context of patients refractory to treatment. The databases used were: Pubmed, LILACS, Cochrane and gray literature. Two researchers, blindly, used the Rayyan reference manager to judge the inclusion and exclusion criteria of the articles. Varied study designs were included, without restrictions on language or year of publication. Disagreements were resolved by a third evaluator. The articles selected for reading went on to data extraction. The studies did not present uniformity in their designs and there was no consensus on the results. Pain improvement was observed in more than 80% of the studies, while the increase in mouth opening was the data that presented the most controversial results. Quality of life analysis remained an unexplored gap.
References
Abboud, W. A. et al. (2017). Localized myofascial pain responds better than referring myofascial pain to botulinum toxin injections. Int J Oral Maxillofac Surg. 46(11), 1417– 23.
Al-Hussain, A. et al. (2021). Effectiveness of Botulinum Toxin in Managing Temporomandibular Disorders: A Systematic Review. J. Health Sci. 7-15.
Ahmed, S. et al. Effect of Local Anesthetic Versus Botulinum Toxin-A Injections for Myofascial Pain Disorders: A Systematic Review and Meta-Analysis. (2019) Clin J Pain. 35(4), 353- 67.
Almuatari, F.A. et al. (2020). The role of botox in the management of tmj disorders – a systematic review. Ann. Dent. Special.8(4), 1-9.
Alshalah, M., Al Jawad, A. J. & Al Jawad, H. J. (2021). Effect of Botox (Botulinum Toxin) on Pain Management for Patiant Suffering from Temporomandibular Joint Disorder & Migraine. Annals of RSCB. 2811-5.
Antonia, M. D. et al. (2013). Jaw muscles myofascial pain and botulinum toxin. Rev. Dor. 14(1), 52-7.
Baker, J. S., Nolan, P. J. (2017). Effectiveness of botulinum toxin type A for the treatment of chronic masticatory myofascial pain: A case series. J Am Dent Assoc. 148 (1), 33-9.
Calis, A. S., Colakoglu, Z. & Gunbay, S. (2019). The use of Botulinum Toxin-A in the treatment of muscular temporomandibular joints disorders. J Stomatol Oral Maxillo Fac Surg. 120(4), 322-5.
Cordeiro, L. & Soares, C.B. (2019). Revisão de escopo: potencialidades para a síntese de metodologias utilizadas em pesquisa primária qualitativa. Bis. 20(2), 37-43. Recuperado em 02 de março de 2024 de https://docs.bvsalud.org/biblioref/2019/10/1021863/bis-v20n2-sintese-de-evidencias-qualitativas-37-43.pdf.
Cruz, D. et al. (2022). Genetic over lap between temporomandibular disorders and primary headaches: A systematic review. Jpn Dent Sci Rev. 58, 69-88.
Daily, Z. et al. (2021). Impact Age in Treatment Myofacial Pain with Temporomandibular Joint Disorders by Botox Injection. Indian Journal of Forensic Medicine & Toxicology. 14, 514- 9.
De-La-Hoz, J. L. et al. (2022). Efficacy of botulinum toxin type A in the management of masticatory myofascial pain: A retrospective clinical study. J Am Dent Assoc. 153(7), 683-91.
De La Torre, C. et al. (2022). Efficacy of Botulinum Toxin Type-A I in the Improvement of Mandibular Motion and Muscle Sensibility in Myofascial Pain TMD Subjects: A Randomized Controlled Trial. Toxins. 14 (7), 441 – 50.
De Carli, B. M. et al. (2016). The effect of laser and botulinum toxin in the treatment of myofascial pain and mouth opening: A randomized clinical trial. (2016). J Photochem Photobiol B. 159,120- 3.
Dressler, D. (2015). Botulinum toxin drugs: brief history and Outlook. J Neural Transm. 123(3), 277- 9.
Eliassen, M. et al. (2019). Self-exercise programmes and occlusal splints in the treatment of TMD-related myalgia-Evidence-based medicine? J Oral Rehabil. 46 (11),1088- 94.
Farrier, J. N. et al. (2020). Can we justify the continued use of botulinum toxin A in the management of myofascial pain? Br J Oral Maxillofac Surg. 58(9), 1133- 8.
Freund, B. J., & Schwartz, M. (2002). Relief of tension-type headache symptoms in subjects with temporomandibular disorders treated with botulinum toxin-A. Headache. 42(10), 1033- 7.
Guarda-Nardini, L. et al. (2012). Myofascial pain of jaw muscles: comparison of short-term effectiveness of botulinum toxin injections and fascial manipulation technique.Cranio. 30 (2), 95-102.
Graff-Radford, S. B., & Abbott, J. J. (2016). Temporomandibular Disorders and Headache. Oral Maxillofac Surg Clin North Am. 28 (3), 335- 49.
Häggman-Henrikson, B. et al. (2017). Pharmacological treatment of orofacial pain – health technology assessment including a systematic review with network meta-analysis. J Oral Rehabil. 44 (10), 800-26.
Headache Classification Committee Of The International Headache Society. (2018). The International Classification of Headache Disorders 3rd edition. Cephalalgia, 38, 1-211.
Jadhao, Va et al. (2017). Efficacy of botulinum toxin in treating myofascial pain and occlusal force characteristics of mastigatory muscles in bruxism. Indian J Dent Res. 28 (5), 493 – 7.
Khan, M. (2018). Short Term Effect of Botulin um Toxin A among Individuals with Headache Attributed to TMD: A Pilot Study. Tese (Mestrado em odontologia) - Faculty of Graduate School, University at Buffalo, State University of New York.
Kocaman, G. et al. Evaluation of Onabotulinumtoxin A Treatment in Patients with Concomitant Chronic Migraine and Temporomandibular Disorders. (2018). Noro Psikiyatr Ars. 55 (4), 330-336.
Kütük, S.G. et al. (2019). Comparison of the efficacies of dry needling and botox methods in the treatment of myofascial pain syndrome affecting the tempomandibular joint. J Craniofac Surg. 30 (5), 1556- 9.
La Fleur, P., Adams, A. (2020). Botulinum Toxin for Temporomandibular Disorders: A review os clinical effectiveness, cost – effectiveness, and Guidelines. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health. HTTPS://www.ncbi.nlm.nih.gov/books/NBK5 62946/
Machado, D. et al. (2019). Botulinum toxin type A for painful temporomandibular disorders: systematic review and meta-analysis. (2019). J Pain. 21 (3), 281-93.
Maixner, W. (2011). Orofacial pain prospective evaluation and risk assessment study - the OPPERA study. J Pain.12 (11), 4- 11.
Montes-Carmona, J. F., Gonzalez-Perez, L. M. & Infante-Cossio, P. (2020). Treatment of Localized and Referred Masticatory Myofascial Pain with Botulinum Toxin Injection. Toxins. 13 (1), 6- 19.
Myers, C. D., White, B. A., & Heft, M. W. (2002). A review of complementary and alternative medicine use for treating chronic facial pain. J Am Dent Assoc.133 (9),1189 – 96.
Oksanen, E, et al. (2022). Temporomandibular Disorder Patients Benefit From Intramuscular Botulinum Toxin Type a Injections. J Craniofac Surg. 33 (1), 1159- 61.
Olla, D. et al. (2020). Migraine Treatment. Clin Plast Surg, 47(2), 295-303.
Patel, A.A., Lerner, M.Z. & Blitzer, A. (2017). Incobotulinum toxin A injection for temporomandibular joint dosorder. Ann Otol Rhinol Laringol. 126 (4), 328- 33.
Réus, J.C. et al. (2022). Association between primary headaches and temporomandibular disorders. A systematic review and meta-analysis. Journal of the American Dental Association. 153 (2), 120- 31.
Sidebottom, A.J., Patel, A.A. & Amin. J. (2013). Botulinum injection for the management of myofascial pain in the masticatory muscles. A prospective outcome study. Br J Oral Maxillofac Surg. 51 (3), 199-205.
Slade, G.D. et al. (2011). Study methods, recruitment, sociodemographic findings, and demographic representativeness in the OPPERA study. J Pain. 12 (11),12-26.
Slade, G.D. et al. (2016). Painful Temporomandibular Disorder: Decade of Discovery from OPPERA Studies. J Dent Res. 95 (10), 1084- 92.
Tchivileva, I.E. et al. (2021). Clinical, psychological, and sensory characteristics associated with headache attributed to temporomandibular disorder in people with chronic myogenous temporomandibular disorder and primary headaches. Headache and Pain. 1, 22-42.
Thambar, S., Kulkarni, S. & Nikolarakos, D. (2020). Botulinum toxin in the management of temporomandibular disorders: a systematic review. Br J Oral Maxillofac Surg. 58(5), 508-19.
Valesan, L.F. et al. (2021). Prevalence of tempomandibular joint disorders: a systematic review and meta-analysis. Clin Oral Investig. 25, 441-53.
Wambier, L. M. et al. (2021). Does the Use of Botulinum Toxin Reduce the Intensity of myofascial Pain in Adult Patients? A Systematic Review and Meta-Analysis. J Dent Oral Epidemiol.1(2), 1- 16.
Weymar, L.B. (2021). Placa oclusal versus toxina botulínica para controle da dor na disfunção temporomandibular: uma revisão sistemática.Tese. (Mestrado em odontologia) - Faculdade de Odontologia da Universidade Federal de Pelotas, Rio Grande do Sul, Brasil.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Danielle Jamylla Barbosa Ribeiro; Renata de Souza Coelho Soares; Ana Isabela Arruda Meira Ribeiro; Layssa Medeiros Santos
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
